Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Long-Term Survival of Men Treated with Docetaxel and Prednisone for Prostate Cancer
Docetaxel offers a small but clinically significant survival advantage to men with metastatic hormone-refractory prostate cancer.
Sign In
Don't yet have a username or password?
Register now for
Journal Watch e-mail alerts and unlimited online
access to articles 6 months after publication.
Subscribe now for
Full, immediate online access to all Journal Watch content and services.
Already a subscriber? Activate your subscription to receive full online access.
Get full site access with a 7-day site pass for $19